Younger patients who received certain chemotherapies for solid tumors or leukemia may not have T-cells capable of becoming effective CAR T-cells. READ MORE
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
Younger patients who received certain chemotherapies for solid tumors or leukemia may not have T-cells capable of becoming effective CAR T-cells.
Long-term data show that a CAR-T therapy induces significant clinical benefit without added adverse events among patients with refractory aggressive non-Hodgkin lymphoma.
CAR T-cell therapy may compliment HSCT for improving survival in ALL without increasing the risk of severe graft-versus-host disease, according to research presented at the 2018 BMT Tandem Meetings.
FDA-approved CAR T-cell therapies may be associated with high costs, but the therapies are priced in alignment with their clinical value, according to an Institute for Clinical and Economic Review evidence report.